Drugs / Prolgolimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05757466 | Apr 2023 → Mar 2024 | classic Hodgkin lymphoma | St. Petersburg State Pavlov Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT06428487 | Mar 2022 → Dec 2024 | colorectal cancer | Blokhin's Russian Cancer Research Center | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT05751928 | Apr 2023 → Jan 2027 expected | cutaneous melanoma | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05732805 | Aug 2022 → Jun 2024 overdue | cutaneous melanoma, metastatic melanoma | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05783882 | Feb 2022 → Jun 2023 | melanoma | Biocad | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-02-23 | SPH-BIOCAD (HK) Limited | Regulatory 上海医药Prolgolimab注射液获得III期临床试验批准通知书 sphchina.com ↗
近日，上海医药集团股份有限公司合资公司上药博康生物医药（香港）有限公司（SPH-BIOCAD（HK）Limited，以下简称“上药博康”） 开发的“Prolgolimab 注射液”收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-23 | SPH-BIOCAD (HK) Limited | 上海医药Prolgolimab注射液获得III期临床试验批准通知书 sphchina.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prolgolimab | “Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions.” NCT05732805 ↗ |
| Known as | BCD-100 | “BCD-100 (prolgolimab)” NCT05732805 ↗ |
| Action | Inhibit | “anti-PD1” NCT05751928 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314998 ↗ |
| Route | Intravenous | “as an intravenous infusion” NCT05732805 ↗ |